222 related articles for article (PubMed ID: 34920895)
1. Health Care Provider Characteristics Associated With Colorectal Cancer Screening Preferences and Use.
Finney Rutten LJ; Parks PD; Weiser E; Fan C; Jacobson DJ; Jenkins GD; Zhu X; Griffin JM; Limburg PJ
Mayo Clin Proc; 2022 Jan; 97(1):101-109. PubMed ID: 34920895
[TBL] [Abstract][Full Text] [Related]
2. National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences.
Zhu X; Parks PD; Weiser E; Fischer K; Griffin JM; Limburg PJ; Finney Rutten LJ
Cancer Prev Res (Phila); 2021 May; 14(5):603-614. PubMed ID: 33888515
[TBL] [Abstract][Full Text] [Related]
3. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
[TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer screening preferences among physicians and individuals at average risk: A discrete choice experiment.
Heidenreich S; Finney Rutten LJ; Miller-Wilson LA; Jimenez-Moreno C; Chua GN; Fisher DA
Cancer Med; 2022 Aug; 11(16):3156-3167. PubMed ID: 35315224
[TBL] [Abstract][Full Text] [Related]
5. Barriers to utilization of three colorectal cancer screening options - Data from a national survey.
Zhu X; Parks PD; Weiser E; Jacobson DJ; Limburg PJ; Finney Rutten LJ
Prev Med Rep; 2021 Dec; 24():101508. PubMed ID: 34401220
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
8. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
Prince M; Lester L; Chiniwala R; Berger B
World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
[TBL] [Abstract][Full Text] [Related]
9. Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening.
Redwood DG; Blake ID; Provost EM; Kisiel JB; Sacco FD; Ahlquist DA
J Prim Care Community Health; 2019; 10():2150132719884295. PubMed ID: 31646933
[No Abstract] [Full Text] [Related]
10. Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening.
Finney Rutten LJ; Jacobson RM; Wilson PM; Jacobson DJ; Fan C; Kisiel JB; Sweetser S; Tulledge-Scheitel SM; St Sauver JL
Mayo Clin Proc; 2017 May; 92(5):726-733. PubMed ID: 28473037
[TBL] [Abstract][Full Text] [Related]
11. PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests.
Pickhardt PJ; Correale L; Hassan C
AJR Am J Roentgenol; 2021 Oct; 217(4):817-830. PubMed ID: 33703913
[No Abstract] [Full Text] [Related]
12. Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States.
Singal AG; Corley DA; Kamineni A; Garcia M; Zheng Y; Doria-Rose PV; Quinn VP; Jensen CD; Chubak J; Tiro J; Doubeni CA; Ghai NR; Skinner CS; Wernli K; Halm EA
Am J Gastroenterol; 2018 May; 113(5):746-754. PubMed ID: 29487413
[TBL] [Abstract][Full Text] [Related]
13. Training primary care physicians to offer their patients faecal occult blood testing and colonoscopy for colorectal cancer screening on an equal basis: a pilot intervention with before-after and parallel group surveys.
Selby K; Cornuz J; Gachoud D; Bulliard JL; Nichita C; Dorta G; Ducros C; Auer R
BMJ Open; 2016 May; 6(5):e011086. PubMed ID: 27178977
[TBL] [Abstract][Full Text] [Related]
14. Performance of multitarget stool DNA testing in African American patients.
Cooper GS; Markowitz SD; Chen Z; Tuck M; Willis JE; Berger BM; Brenner DE; Li L
Cancer; 2018 Oct; 124(19):3876-3880. PubMed ID: 30193399
[TBL] [Abstract][Full Text] [Related]
15. Inappropriate Ordering of Multitarget Stool DNA Tests for Colon Cancer Screening.
Ahn AB; Kulhari S; Rhee J; Cooper G
J Am Board Fam Med; 2024; 37(2):328-331. PubMed ID: 38740492
[TBL] [Abstract][Full Text] [Related]
16. Colorectal cancer screening by primary care physicians: recommendations and practices, 2006-2007.
Klabunde CN; Lanier D; Nadel MR; McLeod C; Yuan G; Vernon SW
Am J Prev Med; 2009 Jul; 37(1):8-16. PubMed ID: 19442479
[TBL] [Abstract][Full Text] [Related]
17. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
Berger BM; Parton MA; Levin B
Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
[TBL] [Abstract][Full Text] [Related]
18. Initial validation of a self-report questionnaire based on the Theoretical Domains Framework: determinants of clinician adoption of a novel colorectal cancer screening strategy.
Zhu X; Lee MK; Weiser E; Griffin JM; Limburg PJ; Finney Rutten LJ
Implement Sci Commun; 2021 Oct; 2(1):119. PubMed ID: 34666841
[TBL] [Abstract][Full Text] [Related]
19. Factors Associated With Clinician Recommendations for Colorectal Cancer Screening Among Average-Risk Patients: Data From a National Survey.
Zhu X; Weiser E; Jacobson DJ; Griffin JM; Limburg PJ; Finney Rutten LJ
Prev Chronic Dis; 2022 Apr; 19():E19. PubMed ID: 35420980
[TBL] [Abstract][Full Text] [Related]
20. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
